Published in partnership with Seoul National University Bundang Hospital



https://doi.org/10.1038/s41746-025-01980-w

# Planet-wide performance of a skin disease Al algorithm validated in Korea

Check for updates

Seung Seog Han<sup>1,14</sup>, Soo Ick Cho<sup>2,14</sup>, Gröger Fabian<sup>3</sup>, Alexander A. Navarini<sup>3</sup>, Myoung Shin Kim<sup>4</sup>, Dong Hun Lee<sup>5</sup>, Ju Hee Lee<sup>6</sup>, Jihee Kim<sup>7</sup>, Chong Hyun Won<sup>7</sup>, Kyung-Nam Bae<sup>8</sup>, Jee-Bum Lee<sup>9</sup>, Hyun-Sun Yoon<sup>10</sup>, Sung Eun Chang<sup>7</sup>, Seong Hwan Kim<sup>11</sup> ⋈, Jung Im Na<sup>12</sup> ⋈ & Cristian Navarrete-Dechent<sup>13</sup>

To address the diversity of skin conditions and the low prevalence of skin cancers, we curated a large hospital dataset (National Information Society Agency, Seoul, Korea [NIA] dataset; 70 diseases, 152,443 images) and collected real-world webapp data (https://modelderm.com; 1,691,032 requests). We propose a conservative evaluation method by assessing sensitivity in hospitals and specificity in real-world use, assuming all malignancy predictions were false positives. Based on three differential diagnoses, skin cancer sensitivity in Korea was 78.2% (NIA) and specificity was 88.0% (webapp). Top-1 and Top-3 accuracies for 70 diseases (NIA) were 43.3% and 66.6%, respectively. Analysis of webapp data provides insights into disease prevalence and public interest across 228 countries. Malignancy predictions were highest in North America (2.6%) and lowest in Africa (0.9%), while benign tumors were most common in Asia (55.5%), and infectious diseases were most prevalent in Africa (17.1%). These findings suggest that AI can aid global dermatologic surveillance.

Artificial intelligence (AI) has demonstrated remarkable performance in dermatology, often surpassing dermatologists in certain controlled conditions<sup>1</sup>. Those studies, mostly encompassing skin cancer and utilizing clinical photographs and dermoscopy images, have shown that AI can outperform dermatologists when diagnoses are based solely on image data<sup>2</sup>
<sup>-5</sup>. The performance of various AI models has been validated using a variety of publicly available dermatology datasets<sup>6–14</sup>.

Unlike in radiology and ophthalmology, vision AI models in dermatology have not been yet clinically successful for several reasons. First, AI performance in dermatological conditions tends to be overestimated in the reader test when conducted with limited information. Unlike radiologists who detect specific findings from X-ray images or ophthalmologists who interpret fundus imaging to determine diabetic retinopathy, dermatologists rely on a variety of contextual and patient-specific information outside of imaging to make a diagnosis. Second, AI performance can decrease due to

out-of-distribution (OOD) cases in real-world situations. While images utilized in radiology or ophthalmology are taken with specialized medical equipment or by medical staffs following DICOM standards, resulting in more standardized samples, most images used in dermatology outside research settings are taken with non-medical equipment such as non-professional consumer cameras or smartphone cameras in a non-standardized manner and are often acquired by non-medical personnel, resulting in frequent OOD scenarios<sup>15</sup>.

Consequently, while AI may outperform dermatologists in purely image-based diagnoses using preprocessed in-distribution datasets, clinicians in real practice tend to be more accurate <sup>16</sup>. Historical examples, such as the MelaFind algorithm, which received FDA approval but ultimately disappeared from the market due to high false-positive rates, highlight how AI algorithms that perform well under controlled conditions can struggle in real-world applications <sup>17</sup>. In addition, the results may be distorted because

<sup>1</sup>I Dermatology Clinic, Seoul, South Korea. <sup>2</sup>InSkin Lab Inc., Seoul, South Korea. <sup>3</sup>Department of Dermatology, University of Basel, Basel, Switzerland. <sup>4</sup>Department of Dermatology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea. <sup>5</sup>Department of Dermatology, Seoul National University Hospital, Seoul National University College of Medicine, Institute of Human-Environment Interface Biology, Medical Research Center, Seoul National University, Seoul, South Korea. <sup>6</sup>Department of Dermatology, Yonsei University College of Medicine, Seoul, South Korea. <sup>7</sup>Department of Dermatology, Asan Medical Center, Ulsan University College of Medicine, Seoul, South Korea. <sup>8</sup>Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea. <sup>9</sup>Department of Dermatology, Chonnam National University Medical School, Kwangju, Korea. <sup>10</sup>Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea. <sup>11</sup>Department of Plastic and Reconstructive Surgery, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea. <sup>12</sup>Department of Dermatology, Seoul National University Bundang Hostpial, Seoul National University College of Medicine, Digital Dermatology Center, Seoul, South Korea. <sup>13</sup>Department of Dermatology, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile. <sup>14</sup>These authors contributed equally: Seung Seog Han, Soo Ick Cho. —mail: kalosmanus@naver.com; jina1@snu.ac.kr

most test sets do not reflect disease prevalence, as the ratio of benign to malignant disease in most test datasets is lower than 10:1. Real-world data is also complicated and influenced by the wide variation in skin color and ethnic skin types which creates unique variations that creates specific challenges to AI algorithms. For these reasons, it is important to measure AI algorithms performance using real-world data, especially when evaluating specificity.

In a prior national validation study performed in Korea, we separately calculated the sensitivity and specificity. In order to precisely assess sensitivity, we created a dataset comparable to the annual number of skin cancer cases in Korea. To evaluate specificity, we analyzed the malignancy predictions made by the algorithm in actual use. Additionally, to assess multiclass performance, we analyzed 152,443 images across 70 diseases. Finally, to understand the implications of worldwide skin variation, we investigated global disease prediction patterns using the algorithm, aiming to get insights into user interests and disease prevalence.

#### Results

## NIA and SNU dataset analysis

The NIA (National Information Society Agency) dataset consists of 152,443 clinical photographs, covering 70 distinct diseases. (Table 1) The SNU (Seoul National University Hospital) test dataset consists of 240 clinical photographs, covering 80 distinct diseases (Supplementary Table 1).

For binary classification of malignancy or not, the algorithm achieved an AUC of 0.946 (95% CI 0.942–0.950) in the NIA dataset, using the data on benign and malignant tumors (n = 51,038 images, 33 diseases). (Fig. 1a) The sensitivity and specificity of the algorithm were calculated through the three differential diagnoses suggested by the algorithm (Top-3), which is an established metric<sup>5</sup>. The sensitivity and specificity of the algorithm were 78.2% (95% CI 77.0–79.4%) and 93.0% (95% CI 92.8–93.3%) for the NIA dataset. For the SNU test dataset, the AUC was 0.958 (95% CI 0.919–0.997). (Fig. 1b) When calculated from the Top-3, sensitivity and specificity were 87.5% (95% CI 0.32–0.938) and 91.0% (95% CI 0.32–0.938) for the SNU test dataset (Supplementary Table 2).

For multi-class classification of matching exact diagnosis, the algorithm achieved micro-averaged mean Top-1 and Top-3 accuracies of 43.3% and 66.6% on the NIA dataset, respectively. (Table 1) The micro-averaged mean Top-1 and Top-3 accuracies showed 63.3% and 83.2% on the SNU test dataset, which were comparable to the 49.9% and 67.2% performance involving 2 dermatologists and 2 dermatology residents in the previous study<sup>4</sup>.

In the reader test (SNU test dataset), involving 61,066 assessments from 138 countries for determining malignancy or not, the mean sensitivity and specificity of global users were 55.2% (95% CI 54.2–56.2%) and 84.3% (95% CI 84.0–84.6%), respectively, which were significantly lower than the performance of the algorithm for the same 61,066 cases (86.8% [95% CI 86.2–87.5%] and 91.0% [95% CI 90.8–91.2%]) (both p < 0.0001, McNemar). (Supplementary Table 3) As shown in Fig. 1b, reader sensitivity was significantly higher in North America (64.0%), Oceania (62.6%), and Europe (59.2%) than in Asia (51.7%), South America (50.6%), and Africa (43.8%) (p < 0.0001, Chi-square with Bonferroni correction).

# Global user performance

Global usage statistics from 1,691,032 requests showed notable regional variations. The distribution of requests by region was as follows: Europe (47.9%), Asia (31.5%), North America (10.1%), South America (5.7%), Africa (2.9%), and Oceania (1.9%). The top five countries by usage were Korea (22.6%), Italy (9.0%), United States (6.2%), Germany (5.9%), and France (4.0%) (Table 2, Supplementary Table 5).

The algorithm's predictions showed distinct regional diagnostic trends. The highest proportion of the algorithm's predictions were for benign tumors, which accounted for 65.2% in Korea. (Table 2) In terms of benign tumor predictions, the ranking by region was as follows ('>' indicates p < 0.0001 by Chi-Square with Bonferroni correction): Asia (55.5%) > Oceania (46.8%) > (p = 1.000) Europe (46.5%) > North America (38.0%) > South America (32.3%) > Africa (22.4%).

Regarding malignancy predictions using Top-1 diagnosis, the rate was 2.1% in Korea. (Table 2) The regional distribution of malignancy predictions was as follows ('>' indicates p < 0.0001 by Chi-Square with Bonferroni correction): North America (2.6%) > Europe (1.9%)  $\approx (p = 0.5402)$  Asia (1.8%)  $\approx (p = 0.9308)$  Oceania (1.7%) > (p = 0.0002) South America (1.4%) > Africa (0.9%).

Infectious conditions were predominantly predicted in Africa and South America than other regions, with higher frequencies observed in the Middle East and Northern Africa on the country map (Fig. 2c). The regional distribution was as follows ('>' indicates p < 0.0001 by Chi-Square with Bonferroni correction): Africa (17.1%) > South America (14.8%) > North America (12.9%) > Europe (11.5%) > Asia (10.0%) > Oceania (8.6%). Unlike other disease groups, allergic diseases showed relatively consistent trends across regions (Fig. 2d).

The ten most commonly predicted diseases were as follows: melanocytic nevus (20.9%), seborrheic keratosis (4.6%), cherry hemangioma (2.2%), dermatofibroma (2.1%), folliculitis (2.0%), wart (2.0%), lentigo (2.0%), hemangioma (2.0%), urticaria (1.9%), and actinic keratosis (1.9%). (Supplementary Table 6) Folliculitis was more prevalent in the Middle East and Southeast Asia on the map, while actinic keratosis was more common in North America and Australia (Fig. 3).

Regarding malignancy diagnosis using Top-3 predictions, the rate was 12.0% (95% CI 11.8–12.1%) in Korea and 10.0% (95% CI 9.9–10.0%) globally. (Supplementary Table 4) Assuming that all malignancy diagnoses by the algorithm were false positives, the estimated specificity using Top-3 in Korea was 88.0% (95% CI 87.9–88.2%), and 90.0% (95% CI 90.0–90.1%) globally. By continent, the malignancy predictions using Top-3 was as follows: North America (11.7%), Asia (10.9%), Europe (9.3%), Oceania (9.0%), South America (8.0%), and Africa (6.7%).

## **Discussion**

Here, we present the worldwide study evaluating the real-clinical use of an open-access global dermatology AI service with 1.69 million assessments from 228 different countries. These large number of requests reflects strong user interest in dermatology AI apps and confirm the utility apps in daily clinical practice. However, evaluating the real-world performance of AI in dermatology is highly challenging because a continuous dataset linking AI results to biopsy outcomes is required. However, due to lack of population-based reference skin cancer datasets and the current lack of digitalization in clinical practice, obtaining large datasets with serial results is virtually impossible <sup>18</sup>. Furthermore, evaluating 'specificity' is problematic, as curated hospital datasets fail to capture the wide range of out-of-distribution conditions encountered in real-world settings.

A substantial discrepancy exists between the performance of diagnoses based on images alone and diagnosing in actual clinical practice. For the diagnosis of 43 tumor types, attending physicians achieved Top-1 and Top-3 accuracies of 68.1% and 77.3%, whereas physicians in the reader test achieved only 37.7% and 53.4% for the same cases, respectively <sup>16</sup>. Although AI has demonstrated exceptional performance in controlled settings, it must prove its effectiveness in real-world environments to be meaningful in clinical practice <sup>19,20</sup>. Despite the large number of retrospective studies, real-world evidence remains insufficient. As of 2024, only 86 medical AI algorithms have reported RCT-level evidence, and among these, 70 achieved successful outcomes, and of these, only 1 exists in the field of dermatology <sup>21,22</sup>.

We curated a large dataset representing cancer cases in Korea to estimate the sensitivity for cancer diagnosis. To assess specificity, we analyzed usage statistics under the assumption that all AI-determined malignancy predictions were false positives. This separated approach enabled us to estimate the algorithm's real-world performance in terms of sensitivity and specificity.

First, regarding the sensitivity, the maximum sensitivity was estimated under the assumption that false negatives are minimal if using the national-scale hospital dataset. The NIA dataset is large enough to represent skin cancer cases in Korea. Therefore, the sensitivity of 78.2% (95% CI,

Algorithm
of the
Accuracies
Top-3
1 and To
Top-1
set and
ata
he NIA D
s of th
Demographic
Table 1

Transport   Property   Property	Category	Disease	NIA Dataset				Algo. (Binary)		Algo. (Multiclass)	
Busine controllment         200         1894         68.0         48.4         62.1% (c) 10.0%-10.5%)         58.1% (c) 10.0%-10.5%)         58.2% (c) 11.0%-10.5%)         58.2% (c) 11.0%-10.			No. of Images	No. of Cases	Average Age	Male (%)	TOP-1	TOP-3	T0P-1	TOP-3
the proposition acroinous Brown         170         181         7.04         46.9         98.4% (C 25 1–46.9%)         76.9% (C 76 1–46.9%)	Malignant Tumors	Basal cell carcinoma	2010	1804	0.69	48.4	62.1% (CI 60.0-64.3%)	81.6% (CI 79.9-83.3%)	55.9% (CI 53.7-58.1%)	73.1% (CI 71.1–75.0%)
Manighaneuron         RES         734         RES         71         adole QL RE-66.0549         77.08 (CT 0.72-77-264)         34.55 (CL 0.22-67-264)           Anniquezon manighaneuron         RES         17.25         48.5         50.256 (CL 0.22-67-264)         34.55 (CL 0.22-67-264)         37.14 (CL 0.22-67-264)<		Intraepithelial carcinoma (Bowen disease)	170	111	70.6	45.9	39.4% (CI 32.1–46.8%)	67.6% (CI 60.6–74.7%)	28.2% (CI 21.5–35.0%)	53.5% (CI 46.0-61.0%)
Columnia in India         1671         7.4.2         48.5         9.0.2.W IGT 17-6.5.79         7.1.2.W 12.0.0.           Columnia in India         1627         7.0.2         48.0         9.0.2.W IGT 17-6.5.39         7.1.3.W 72.0.0.         4.1.0         9.0.2.W 12.0.0.		Malignant melanoma	825	734	63.7	51.1	49.0% (CI 45.6–52.4%)	73.9% (CI 70.9–76.9%)	47.3% (CI 43.9–50.7%)	66.8% (CI 63.6-70.0%)
And the information of a control o		Squamous cell carcinoma	1804	1601	74.2	48.5	50.2% (CI 47.9-52.5%)	77.3% (CI 75.3-79.2%)	33.3% (CI 31.1-35.5%)	60.0% (CI 57.7-62.2%)
Active Lemmonia         1823         1405         73.7         32.4         a 20.9% (2015-24.5%)         26.7% (2015-24.5%)         26.9% (2015-24.5%)         26.0% (2015-24.5%)		Total (Malignant Tumors)	4250	4809	70.1	48.9	°50.2% b54.6%	a75.1% b78.2%	a41.2% b45.0%	°63.3% b66.4%
Decker means         872         672         14.8         68.8         10.000% (C1100G+1000W)         699.8 (C1961-266.0)         64.1% (C1606-46.0)           Dilon mean         11.3         10.6         13.2         12.2         10.00% (C1002-10.00%)         699.8 (C1802-26.00%)         61.1% (C1602-46.00%)           Catisa militarmeule         11.3         11.2         57.7         42.0         10.00% (C1002-26.00%)         699.8 (C1802-27.00%)         61.2% (C1802-27.00%)           Companitarmeule         18.3         11.3         61.2         28.4         12.2% (C1802-27.00%)         61.2% (C1802-27.00%)         61.2% (C1802-27.00%)           Companitarmeule         18.3         11.3         40.2         98.9% (C1802-28.03%)         97.7% (C1802-28.00%)         61.2% (C1802-27.00%)           Lipidemial cyst         11.2         40.2         28.7         98.9% (C1802-28.00%)         97.7% (C1802-28.00%)         61.2% (C1802-27.00%)         <	Benign Tumors	Actinic keratosis	1823	1405	73.7	37.4	92.9% (CI 91.7-94.1%)	58.1% (CI 55.8-60.4%)	40.9% (CI 38.7-43.2%)	69.9% (CI 67.8-72.0%)
Demonstration         113         115         115         115         115         115         115         115         115         115         115         117         <		Becker nevus	872	672	14.8	63.8	100.0% (CI 100.0-100.0%)	99.9% (CI 99.7-100.1%)	54.1% (CI 50.8-57.4%)	72.9% (CI 70.0-75.9%)
Carie au lait monoile         2445         1648         57         480         1000% (D1 100-1000%)         589% (C1 980 + C1000%)         51.7% (C1 310-268.3%)         51.7% (C1 310-26.0%)		Blue nevus	113	105	33.0	45.7	92.9% (CI 88.2-97.6%)	71.7% (CI 63.4-80.0%)	60.2% (CI 51.2-69.2%)	75.2% (CI 67.3-83.2%)
Conjust         1472         54.7         40.0         96.9% (1962-96-96-8)         97.7% (1917-66-84)         26.9% (1962-50-16-8)           Conjustation was all properties and properties		Cafe au lait macule	2445	1648	5.7	45.0	100.0% (CI 100.0-100.0%)	99.9% (CI 99.7-100.0%)	51.7% (CI 49.8-53.7%)	77.5% (CI 75.9–79.2%)
Congenital nevues         1343         1546         8.1         47.2         88-9% (C) 86 3-80 3%         16.8% (C) 68 0-86 5%         51.8% (C) 48 0-54 0%           Deprendent/locum         1745         1156         40.9         22.0         99.7% (C) 86 0-100 5%         55.8% (C) 84 0-85 0%         51.8% (C) 48 0-54 0%           Epidemund (prant         27.2         25.0         30.7% (C) 86 0-100 5%         56.8% (C) 86 0-85 0%         57.4% (C) 86 0-85 0%		Callus	1807	1472	54.7	40.0	99.5% (CI 99.2-99.8%)	97.7% (CI 97.0-98.4%)	28.4% (CI 26.3-30.5%)	70.3% (CI 68.2-72.4%)
Commendation         1345         40.9         29.0         69.9% (C) 96.4–10.00%         65.9% (C) 46.4–66.70%         68.9% (C) 64.5–7.14%           Epidemini oyst         27.32         25.15         33.4         69.3% (C) 86.4–10.00%         97.4% (C) 68.6–26.9%         97.8% (C) 68.2–6.00%           Epidemini oyst         12.9         31.3         99.9% (C) 86.4–10.00%         97.4% (C) 68.6–26.4%         90.3% (C) 86.7–10.64           Hemangioma         37.10         33.15         2.9         31.3         99.9% (C) 86.7–10.00%         96.9% (C) 86.7–86.4%         90.9% (C) 86.7–86.4%         90.3% (C) 86.7–96.4%         90.3% (C) 86.7		Congenital nevus	1933	1546	8.1	47.2	98.8% (CI 98.3-99.3%)	84.6% (CI 83.0-86.2%)	51.8% (CI 49.6-54.0%)	76.0% (CI 74.1–78.0%)
Epidemuli opat         272         25-16         36.4         63.7         99.9% (C196.0-96.8%)         77.4% (C196.8-96.8%)         52.7% (C156.2-54.0%)           Epidemuli opats         1256         31.1         10.1         44.4         99.9% (C196.1-90.0%)         58.6% (C196.1-96.4%)         96.1% (C196.2-96.0%)           Epidemuli onus         1256         31.5         24.8         24.3         96.9% (C196.1-96.0%)         96.5% (C196.1-96.4%)		Dermatofibroma	1245	1136	40.9	29.0	99.7% (CI 99.4-100.0%)	95.9% (CI 94.8-97.0%)	68.8% (CI 66.3-71.4%)	84.9% (CI 82.9-86.9%)
Epidemmal newus         1256         801         101         484         989% (C1969-E-10011%)         68.8% (C1963-G-96.5%)         45.9% (C1961-G-66.4%)           Hemanagiona         310         3315         2.9         31.3         98.9% (C1968-F-10011%)         98.8% (C1967-G-96.5%)         61.8% (C1461-L-66.4%)         45.9% (C1961-G-66.4%)         45.9% (C1961-G-		Epidermal cyst	2732	2516	36.4	53.7	99.3% (CI 99.0-99.6%)	97.4% (CI 96.8-98.0%)	52.1% (CI 50.2-54.0%)	74.5% (CI 72.9–76.2%)
Hemmangloma         3110         315         2.9         313         899% (Cl 98 - HollOLOW)         95.8% (Cl 95.1 - 96.4%)         95.8% (Cl 95.2 - 96.4%)		Epidermal nevus	1256	801	10.1	49.4	99.9% (CI 99.8-100.1%)	98.9% (CI 98.3-99.5%)	45.9% (CI 43.1-48.6%)	68.1% (CI 65.5-70.7%)
Hypertrophic scart         489         361         2.84         96.6% (Cl 97.5–98.6%)         96.1% (Cl 94.4–97.8%)         10.6% (Cl 10.1.2.6%)           Juvenile xanthogranuloma         1050         753         2.8         606         100.00% (Cl 10.00-10.00%)         98.2% (Cl 98.7–98.8%)         51.9% (Cl 84.1–94.2%)           Keided         2222         1434         2.95         2.02         98.2% (Cl 98.7–98.6%)         36.0% (Cl 98.7–98.6%)         45.8% (Cl 48.1–94.2%)           Melanopycha         2822         2.92         2.02         2.02         89.0% (Cl 98.7–10.00%)         81.2% (Cl 80.2–86.6%)         81.7% (Cl 48.5–41.0%)           Melanopycha         2182         2.94         1.6         1.02.% (Cl 89.7–10.00%)         81.2% (Cl 81.8–95.1%)         58.3% (Cl 81.8–95.1%)         81.3% (Cl 81.8–95.9%)		Hemangioma	3710	3315	2.9	31.3	99.9% (CI 99.8-100.0%)	95.8% (CI 95.1-96.4%)	90.3% (CI 89.4-91.3%)	96.0% (CI 95.3-96.6%)
Juvenille xanthogranuloma         1050         753         2.8         6.0.6         1000% (C1100 D-100.0%)         99.2% (C1987-98.9%)         51.1% (C181-64.2%)           Keidod         2262         1428         26.5         42.8         99.2% (C198-99.9%)         99.2% (C198-798.0%)         51.1% (C181-64.2%)           Lenido         2262         1428         26.5         42.8         99.2% (C198-99.9%)         81.2% (C198-7-80.0%)         45.1% (C181-64.2%)           Melanocytic nevas         3803         2849         25.8         41.0         20.2         98.8% (C198-7-100.0%)         81.2% (C181-62.6%)         81.2% (C181-62.6		Hypertrophic scar	489	361	24.8	29.4	98.6% (CI 97.5-99.6%)	96.1% (CI 94.4–97.8%)	10.8% (CI 8.1-13.6%)	57.9% (CI 53.5-62.2%)
Keloid         2262         1494         28.5         42.8         99.2% (C) 98.6-98.5%         40.0% (C) 93.0-66.0%         45.8% (C) 143.8-41.79%           Lentigo         1878         890         52.2         20.2         98.8% (C) 98.7-100.0%         96.0% (C) 97.3-98.6%         45.8% (C) 143.8-41.79%           Melanocytic nevus         3803         2949         25.8         41.0         98.3% (C) 189.7-100.0%         93.5% (C) 91.9-5-98.7%         42.7% (C) 80.0-98.5%         48.7% (C) 80.0-98.6%		Juvenile xanthogranuloma	1050	753	2.8	9.09	100.0% (CI 100.0-100.0%)	99.2% (CI 98.7-99.8%)	51.1% (CI 48.1-54.2%)	68.5% (CI 65.7-71.3%)
Lentigo         1878         890         59.2         20.2         99.8% (Cl 99.7-90.0%)         99.0% (Cl 97.3-96.6%)         48.7% (Cl 46.5-6.10%)           Melancoychic nevus         3803         29.49         25.8         41.0         98.3% (Cl 97.3-98.7%)         81.2% (Cl 80.0-82.5%)         68.8% (Cl 63.3-71.2%)           Melancoychic nevus         2162         14.8         16.5         5.3         99.9% (Cl 99.7-100.0%)         10.2% (Cl 81.9-85.7%)         68.3% (Cl 81.9-85.2%)         68.3% (Cl 81.9-85.2%)         68.3% (Cl 81.9-85.7%)         68.3% (Cl 81.9-85.2%)         68.3% (Cl 81.9-85.2%)         68.3% (Cl 81.9-85.2%) <td></td> <td>Keloid</td> <td>2262</td> <td>1494</td> <td>29.5</td> <td>42.8</td> <td>99.2% (CI 98.8-99.5%)</td> <td>94.0% (CI 93.0-95.0%)</td> <td>45.8% (CI 43.8-47.9%)</td> <td>68.7% (CI 66.8-70.6%)</td>		Keloid	2262	1494	29.5	42.8	99.2% (CI 98.8-99.5%)	94.0% (CI 93.0-95.0%)	45.8% (CI 43.8-47.9%)	68.7% (CI 66.8-70.6%)
Melanocytic nevus         3803         2949         2.5         41.0         98.3% (CI 97.9-98.7%)         81.2% (CI 80.0-62.5%)         69.8% (CI 80.1-26.1%)           Melanorychia         162         1448         16.5         53.8         99.9% (CI 90.7-100.0%)         83.5% (CI 81.3-66.1%)         58.3% (CI 80.2-60.4%)           Milanorychia         1155         459         44.1         22.7         100.0% (CI 100.0-100.0%)         93.3% (CI 81.3-66.1%)         58.3% (CI 81.2-66.1%)           Organici nevus         1911         1362         3.9         51.8         100.0% (CI 100.0-100.0%)         93.3% (CI 82.9-86.7%)         77.8% (CI 82.0-30.2%)           Organici nevus         1934         123         10.4         51.8         100.0% (CI 100.0-100.0%)         91.% (CI 80.9-86.5%)         77.8% (CI 82.0-32.2%)           Organici nevus         1932         17.1         38.2         100.0% (CI 100.0-100.0%)         91.% (CI 80.9-86.5%)         77.8% (CI 82.6-36.5%)           Organici nevus         288         1937         32.2         100.0% (CI 100.0-100.0%)         91.% (CI 80.9-86.5%)         77.8% (CI 80.9-86.5%)           Organici nevus         288         134         27.2         100.0% (CI 100.0-100.0%)         91.% (CI 80.9-86.5%)         77.8% (CI 80.9-86.5%)         77.8% (CI 80.9-86.5%)         77.8% (CI 80.9-		Lentigo	1878	890	59.2	20.2	99.8% (CI 99.7-100.0%)	98.0% (CI 97.3-98.6%)	48.7% (CI 46.5-51.0%)	80.2% (CI 78.4-82.0%)
Melanonychia         2162         1448         16.5         53.8         99.9% (C) 89.7~100.0%         83.5% (C) 81.9-85.1%         58.3% (C) 86.2~60.4%           Melanonychia         1155         459         44.1         22.7         100.0% (C) 100.0~100.0%         99.3% (C) 88.98.9%         77.6% (C) 26.0-30.2%           Malui         1155         459         14.1         22.7         100.0% (C) 100.0~100.0%         99.3% (C) 88.98.9%         77.6% (C) 86.2~60.4%           Organnoid nevus         1334         1233         10.4         51.8         100.0% (C) 100.0~100.0%         77.7% (C) 86.9.88.5%         78.4% (C) 76.2~98.5%           Organnoid nevus         1334         123         10.4         51.8         100.0% (C) 100.0~100.0%         77.7% (C) 86.9.88.5%         78.4% (C) 76.2~98.5%           Organnoid nevus         349         718         8.7         36.2         100.0% (C) 100.0~100.0%         91.7% (C) 86.4~98.5%         78.4% (C) 76.2~98.5%         78.2% (C) 76.2~98.5%		Melanocytic nevus	3803	2949	25.8	41.0	98.3% (CI 97.9-98.7%)	81.2% (CI 80.0-82.5%)	69.8% (CI 68.3-71.2%)	91.5% (CI 90.6-92.4%)
Milia         1155         459         44.1         22.7         1000% (C1100.0–100.0%)         93.% (C) 88.8–98.8%         27.6% (C125.0–30.2%)           News depigmentosus         1911         1362         3.9         51.8         100.0% (C1100.0–100.0%)         100.0% (C1100.0–100.0%)         93.% (C) 88.8–98.8%         27.6% (C125.0–30.2%)           News depigmentosus         1911         1362         3.9         51.8         100.0% (C1100.0–100.0%)         17.7% (C) 86.9–86.8%         78.4% (C175.2–80.6%)           Organicid nevus         1334         1233         10.4         51.8         100.0% (C1100.0–100.0%)         91.7% (C) 86.9–86.8%         78.4% (C175.2–80.6%)           Opa nevus         2689         1997         92         43.1         100.0% (C1100.0–100.0%)         91.7% (C) 86.9–86.7%         78.4% (C175.2–80.6%)           Properior granuloma         657         630         17.1         52.2         99.1% (C198.4–99.8%)         91.4% (C198.2–90.7%)         62.7% (C160.9–64.5%)           Sebaceus hyperplasia         657         630         63.7         63.5         91.9% (C198.4–99.8%)         91.4% (C198.2–90.7%)         62.2% (C198.2–90.7%)         62.7% (C160.9–64.5%)           Sebaceus hyperplasia         657         43.5         73.9% (C198.2–90.7%)         96.2% (C198.2–90.7%)         96.2% (		Melanonychia	2162	1448	16.5	53.8	99.9% (CI 99.7-100.0%)	83.5% (CI 81.9-85.1%)	58.3% (CI 56.2-60.4%)	79.7% (CI 78.0-81.4%)
News depigmentosus         1911         1362         3.9         51.8         100.0% (CI100.0-100.0%)         10.0% (CI100.0-100.0%)         37.3% (CI35.1-39.5%)           Orgamoid nevus         1334         1233         10.4         51.8         100.0% (CI100.0-100.0%)         97.7% (CI 96.9-86.5%)         78.4% (CI162-80.6%)           Orgamoid nevus         949         718         8.7         38.2         100.0% (CI100.0-100.0%)         97.7% (CI 96.9-86.5%)         78.4% (CI 76.2-80.6%)           Portwine stain         2689         1997         627         43.1         100.0% (CI 100.0-100.0%)         99.4% (CI 96.2-98.7%)         627% (CI 96.2-86.5%)           Pyogenic granuloma         657         630         17.1         52.2         99.1% (CI 98.4-98.8%)         89.6% (CI 98.2-92.7%)         627% (CI 98.2-86.5%)           Sebaceus hyperplasia         657         630         17.1         52.2         99.1% (CI 98.4-98.8%)         89.6% (CI 98.2-99.7%)         62.7% (CI 68.2-60.7%)           Sebaceus hyperplasia         657         63         75.9         99.2% (CI 98.4-98.8%)         89.6% (CI 98.2-99.7%)         58.8% (CI 68.2-98.7%)         62.8% (CI 68.2-96.7%)           Skin tag         126         63         74.2         14.9         100.0% (CI 100.0-10.0%)         99.5% (CI 98.2-98.7%)         62.8% (CI		Milia	1155	459	44.1	22.7	100.0% (CI 100.0-100.0%)	99.3% (CI 98.8-99.8%)	27.6% (CI 25.0-30.2%)	58.1% (CI 55.2-60.9%)
Orgamoid nevus         1334         1233         10.4         51.8         100.00% (CI100.0-100.0%)         97.7% (CI 96.9-98.5%)         78.4% (CI 76.2-80.6%)           Orgamoid nevus         949         718         8.7         38.2         100.0% (CI100.0-100.0%)         97.7% (CI 98.4-99.7%)         40.5% (CI 37.3-43.6%)           Organic nevus         2689         1997         9.2         43.1         100.0% (CI 100.0-100.0%)         97.4% (CI 99.2-97.2%)         52.7% (CI 60.9-64.5%)           Progenic granuloma         657         630         17.1         52.2         99.1% (CI 98.4-98.8%)         96.8% (CI 98.2-97.2%)         53.3% (CI 92.5-57.2%)           Sebaceus hyperplasia         1340         609         53.2         75.9         99.8% (CI 99.5-100.0%)         91.2% (CI 96.2-97.2%)         53.3% (CI		Nevus depigmentosus	1911	1362	3.9	51.8	100.0% (CI 100.0-100.0%)	100.0% (CI 100.0-100.0%)	37.3% (CI 35.1-39.5%)	82.4% (CI 80.7-84.1%)
Ota newus         949         718         8.7         38.2         100.0% (CI100.0-100.0%)         99.1% (CI 98.4-99.7%)         40.5% (CI 37.3-43.6%)           Portwine stain         2689         1997         9.2         43.1         100.0% (CI100.0-100.0%)         99.4% (CI 99.2-99.7%)         62.7% (CI 60.9-64.5%)           Pyogenic granuloma         657         630         17.1         52.2         99.1% (CI 98.4-98.8%)         89.6% (CI 99.2-90.7%)         62.7% (CI 60.9-64.5%)           Sebaceus hyperplasia         1340         609         53.2         75.9         99.8% (CI 99.5-100.0%)         96.2% (CI 95.2-97.2%)         32.1% (CI 29.6-34.6%)           Seborrheic keratosis         1236         637         53.5         97.9% (CI 99.4-100.0%)         99.4% (CI 98.9-99.8%)         32.1% (CI 29.6-34.6%)           Skin tag         1236         36.2         44.2         14.9         100.0% (CI 100.0-100.0%)         99.4% (CI 98.9-99.8%)         34.1% (CI 31.5-81.8%)           Syringoma         1268         55.2         44.2         14.9         100.0% (CI 100.0-100.0%)         99.5% (CI 98.9-99.8%)         34.1% (CI 98.1-99.9%)         34.1% (CI 98.1-99.9%)           Syringoma         25.5         44.5         14.9         100.0% (CI 100.0-100.0%)         99.2% (CI 98.2-99.9%)         34.9% (CI 98.2-99.9%)         <		Orgamoid nevus	1334	1233	10.4	51.8	100.0% (CI 100.0-100.0%)	97.7% (CI 96.9-98.5%)	78.4% (CI 76.2-80.6%)	90.9% (CI 89.4-92.5%)
Portwine stain         2689         1997         9.2         43.1         100.0% (CI 100.0–100.0%)         99.4% (CI 99.2–99.7%)         62.7% (CI 60.9–64.5%)           Pyogenic granuloma         657         630         17.1         52.2         99.1% (CI 98.4–99.8%)         86.6% (CI 87.3–82.0%)         53.3% (CI 49.5–57.1%)           Sebaceus hyperplasia         1340         609         53.2         75.9         99.8% (CI 98.5–100.0%)         96.2% (CI 95.2–97.2%)         32.1% (CI 29.6–34.6%)           Sebaceus hyperplasia         1236         63.7         53.5         97.9% (CI 99.5–100.0%)         96.2% (CI 95.2–97.2%)         32.1% (CI 29.6–34.6%)           Skin tag         1236         63.7         49.3         54.0         99.7% (CI 99.4–100.0%)         99.4% (CI 98.2–99.8%)         58.8% (CI 23.4–28.8%)           Skin tag         1236         44.2         14.9         100.0% (CI 100.0–100.0%)         99.5% (CI 99.1–99.9%)         25.8% (CI 23.4–28.2%)           Syringoma         1268         55.2         44.1         44.1         49.90 % (CI 99.2–99.5%)         99.5% (CI 99.1–99.9%)         25.8% (CI 23.4–28.2%)           Syringoma         25.8         27.3         60.0         99.2% (CI 99.2–99.5%)         95.2% (CI 99.2–99.5%)         25.8% (CI 23.4–28.2%)           Acnel (Benign Tumors)         1		Ota nevus	949	718	8.7	38.2	100.0% (CI 100.0-100.0%)	99.1% (CI 98.4-99.7%)	40.5% (CI 37.3-43.6%)	61.5% (CI 58.4-64.6%)
Pyogenic granuloma         657         630         17.1         52.2         99.1% (CI 98.4-99.8%)         89.6% (CI 87.3-92.0%)         53.3% (CI 49.5-57.1%)           Sebaceus hyperplasia         1340         609         53.2         75.9         99.8% (CI 99.5-100.0%)         96.2% (CI 95.2-97.2%)         32.1% (CI 29.6-34.6%)           Seborrheic keratosis         2551         1982         63.7         53.5         97.9% (CI 97.4-98.5%)         80.2% (CI 78.7-81.8%)         58.8% (CI 59.6-90.7%)           Skin tag         1236         798         44.2         14.9         100.0% (CI 100.0-10.00%)         99.5% (CI 98.1-99.8%)         34.1% (CI 31.5-36.8%)           Syringoma         1268         552         44.2         14.1         *99.0% *99.2%         *95.8% (CI 98.1-99.8%)         34.1% (CI 31.6-28.2%)           Syringoma         22.851         44.7         *99.0% *99.2%         *95.8% (CI 98.1-99.8%)         65.8% (CI 31.6-62.8%)         49.2% (CI 98.2-99.8%)         65.8% (CI 53.1-62.8%)           Ache         6537         20.7         60.0         99.2% (CI 99.2-90.5%)         95.2% (CI 98.2-99.8%)         62.2% (CI 91.0-63.3%)           Herpes simplex         1450         887         33.8         73.7         99.9% (CI 99.2-90.0%)         99.2% (CI 98.2-90.8%)         95.2% (CI 98.2-90.8%)         95.2%		Portwine stain	2689	1997	9.2	43.1	100.0% (CI 100.0-100.0%)	99.4% (CI 99.2-99.7%)	62.7% (CI 60.9-64.5%)	85.1% (CI 83.7-86.4%)
Sebaceus hyperplasia         1340         609         53.2         75.9         99.8% (CI 99.5-100.0%)         96.2% (CI 96.2-97.2%)         32.1% (CI 28.6-34.6%)           Seborrheic keratosis         2551         1982         63.7         53.5         97.9% (CI 97.4-98.5%)         80.2% (CI 78.7-81.8%)         58.8% (CI 56.9-60.7%)           Skin tag         1236         49.3         49.3         54.0         99.7% (CI 99.4-100.0%)         99.4% (CI 98.9-99.8%)         34.1% (CI 31.5-36.8%)           Syningoma         1268         55.2         44.2         14.9         100.0% (CI 100.0-100.0%)         99.2% (CI 99.4-99.8%)         34.1% (CI 31.5-36.8%)           Syningoma         32,851         44,670         26.8         44.1         *99.0% (CI 99.4-100.0%)         99.2% (CI 99.4-99.5%)         95.2% (CI 94.5-95.9%)         64.7% (CI 61.0-62.2%)           Ache         65.7         24.5         27.4         51.1         99.9% (CI 99.8-100.0%)         99.2% (CI 98.8-99.5%)         95.2% (CI 98.8-99.6%)         62.2% (CI 61.0-63.3%)           Ache         65.7         27.4         51.1         99.9% (CI 99.8-100.1%)         99.2% (CI 98.8-99.6%)         95.2% (CI 98.8-99.6%)         39.8% (CI 37.6-42.1%)           Herpes simplex         145.0         34.0         45.5         97.2% (CI 96.2-99.1%)         99.2% (CI		Pyogenic granuloma	657	630	17.1	52.2	99.1% (CI 98.4–99.8%)	89.6% (CI 87.3-92.0%)	53.3% (CI 49.5-57.1%)	81.4% (CI 78.5–84.4%)
Seborrheic keratosis         2551         1982         63.7         63.5         97.9% (CI 97.4-98.5%)         80.2% (CI 78.7-81.8%)         58.8% (CI 66.9-60.7%)           Skin tag         1236         49.3         49.3         54.0         99.7% (CI 99.4-100.0%)         99.4% (CI 98.9-98.8%)         34.1% (CI 31.5-36.8%)           Syringoma         1268         55.2         44.2         14.9         100.0% (CI 100.0-100.0%)         99.5% (CI 99.1-99.9%)         35.8% (CI 23.4-28.2%)           Owart         22.85         24.2         26.8         44.1         *99.0% (CI 100.0-100.0%)         99.5% (CI 99.1-99.9%)         65.2% (CI 91.2-4-28.2%)           Ache         35.51         24.55         20.7         60.0         99.2% (CI 98.9-99.5%)         95.2% (CI 94.5-95.9%)         64.7% (CI 63.1-66.2%)           Ache         65.37         24.5         27.4         51.1         99.9% (CI 98.8-99.5%)         99.2% (CI 98.8-99.5%)         99.2% (CI 98.8-99.6%)         99.2% (CI 98.8-99.6%		Sebaceus hyperplasia	1340	609	53.2	75.9	99.8% (CI 99.5-100.0%)	96.2% (CI 95.2-97.2%)	32.1% (CI 29.6-34.6%)	60.2% (CI 57.6-62.8%)
Skin tag         1236         798         49.3         54.0         99.7% (CI 99.4-100.0%)         99.4% (CI 98.9-99.8%)         34.1% (CI 31.5-36.8%)           Syringoma         1268         552         44.2         14.9         100.0% (CI 100.0-100.0%)         95.5% (CI 99.1-99.9%)         25.8% (CI 23.4-28.2%)           Total (Benign Tumors)         32.851         44.670         26.8         44.1         *99.0% (CI 98.9-99.5%)         95.2% (CI 94.5-95.9%)         64.7% (CI 63.1-66.2%)           Acue         6537         24.35         27.4         51.1         99.9% (CI 98.9-99.5%)         95.2% (CI 94.5-95.9%)         67.2% (CI 61.0-63.3%)           Folliculities         1780         1005         38.0         73.7         99.9% (CI 96.3-96.0%)         99.2% (CI 98.8-99.6%)         39.8% (CI 98.8-99.6%)         39.8% (CI 81.0-63.3%)           Herpes simplex         1450         87         45.5         97.2% (CI 96.3-98.0%)         89.9% (CI 96.3-98.0%)         89.9% (CI 96.3-99.6%)         13.7% (CI 12.0-15.5%)           Herpes scoter         42.1         38.7         53.3         46.8         97.6% (CI 96.2-99.1%)         96.7% (CI 96.2-99.1%)         49.9% (CI 96.1-65.7%)		Seborrheic keratosis	2551	1982	63.7	53.5	97.9% (CI 97.4-98.5%)	80.2% (CI 78.7-81.8%)	58.8% (CI 56.9-60.7%)	82.5% (CI 81.0-84.0%)
Syingoma         1268         552         44.2         14.9         100.0% (CI100.0-100.0%)         99.5% (CI 99.1-99.9%)         25.8% (CI 23.4-28.2%)           Total (Benign Tumors)         32,851         44,670         26.8         44.1         *99.0% (CI 99.2%)         95.2% (CI 99.1-99.9%)         55.8% (CI 23.4-28.2%)           **Owart         3551         2435         20.7         60.0         99.2% (CI 98.9-99.5%)         95.2% (CI 94.5-95.9%)         64.7% (CI 63.1-66.2%)           Acne         6537         3235         21.4         51.1         99.9% (CI 98.9-100.0%)         99.7% (CI 98.8-99.6%)         62.2% (CI 61.0-63.3%)           Folliculitis         1780         1005         38.0         73.7         99.9% (CI 96.3-98.0%)         89.9% (CI 98.8-99.6%)         33.8% (CI 12.0-15.5%)           Herpes simplex         1450         87         45.5         97.2% (CI 96.2-99.1%)         96.7% (CI 96.2-99.1%)         49.9% (CI 96.2-16.7%)		Skin tag	1236	798	49.3	54.0	99.7% (CI 99.4-100.0%)	99.4% (CI 98.9-99.8%)	34.1% (CI 31.5-36.8%)	63.6% (CI 60.9-66.3%)
Total (Benign Tumors)         32,851         44,670         26.8         44.1         *99.0% b99.2%         *92.8% *92.4%         *492.8% *92.4%         *492.8% *95.5%           *Wart         *Wart         2435         20.7         60.0         99.2% (CI 98.9-99.5%)         95.2% (CI 94.5-95.9%)         64.7% (CI 63.1-66.2%)           Acne         6537         21.4         51.1         99.9% (CI 98.9-90.5%)         95.2% (CI 94.5-99.8%)         62.2% (CI 61.0-63.3%)           Folliculitis         1780         1005         38.0         73.7         99.9% (CI 99.8-100.1%)         99.2% (CI 98.8-99.6%)         39.8% (CI 37.6-42.1%)           Herpes simplex         1450         887         34.0         45.5         97.2% (CI 96.3-98.0%)         89.9% (CI 88.3-91.4%)         13.7% (CI 12.0-15.5%)           Herpes zoster         421         387         53.3         46.8         97.6% (CI 96.2-991.9%)         96.7% (CI 95.0-98.4%)         49.9% (CI 45.1-54.7%)		Syringoma	1268	552	44.2	14.9	100.0% (CI 100.0-100.0%)	99.5% (CI 99.1–99.9%)	25.8% (CI 23.4-28.2%)	53.5% (CI 50.8-56.3%)
•Wart         2455         20.7         60.0         99.2% (CI 98.9-99.5%)         95.2% (CI 94.5-95.9%)         64.7% (CI 63.1-66.2%)           Acree         Acree         6537         21.4         51.1         99.9% (CI 99.8-100.0%)         99.7% (CI 99.8-99.8%)         62.2% (CI 61.0-63.3%)           Folliculitis         1780         1005         38.0         73.7         99.9% (CI 99.8-100.1%)         99.2% (CI 98.8-99.6%)         39.8% (CI 37.6-42.1%)           Herpes simplex         1450         887         34.0         45.5         97.2% (CI 96.3-98.0%)         89.9% (CI 88.3-91.4%)         13.7% (CI 12.0-15.5%)           Herpes zoster         421         387         53.3         46.8         97.6% (CI 96.2-991.%)         96.7% (CI 95.0-98.4%)         49.9% (CI 45.1-54.7%)		Total (Benign Tumors)	32,851	44,670	26.8	44.1	*99.0% b99.2%	*92.8% b92.4%	<sup>a</sup> 49.2% <sup>b</sup> 53.5%	a74.3% b77.6%
6537         2235         21.4         51.1         99.9% (CI 99.9-100.0%)         99.7% (CI 99.5-99.8%)         62.2% (CI 61.0-63.3%)           1780         1005         38.0         73.7         99.9% (CI 99.8-100.1%)         99.2% (CI 98.8-99.6%)         39.8% (CI 37.6-42.1%)           1450         887         34.0         45.5         97.2% (CI 96.3-98.0%)         89.9% (CI 88.3-91.4%)         13.7% (CI 12.0-15.5%)           421         387         53.3         46.8         97.6% (CI 96.2-99.1%)         96.7% (CI 95.0-98.4%)         49.9% (CI 45.1-54.7%)	Infectious Disorders	°Wart	3551	2435	20.7	0.09	99.2% (CI 98.9-99.5%)	95.2% (CI 94.5-95.9%)	64.7% (CI 63.1-66.2%)	81.7% (CI 80.4-83.0%)
1780         1005         38.0         73.7         99.9% (CI 99.8–100.1%)         99.2% (CI 98.8–99.6%)         33.8% (CI 37.6–42.1%)           1450         887         34.0         45.5         97.2% (CI 96.3–98.0%)         89.9% (CI 88.3–91.4%)         13.7% (CI 12.0–15.5%)           421         387         53.3         46.8         97.6% (CI 96.2–99.1%)         96.7% (CI 95.0–98.4%)         49.9% (CI 45.1–54.7%)		Acne	6537	3235	21.4	51.1	99.9% (CI 99.9-100.0%)	99.7% (CI 99.5-99.8%)	62.2% (CI 61.0-63.3%)	87.9% (CI 87.1-88.6%)
1450         887         34.0         45.5         97.2% (CI 96.3–98.0%)         89.9% (CI 88.3–91.4%)         13.7% (CI 12.0–15.5%)           421         387         53.3         46.8         97.6% (CI 96.2–99.1%)         96.7% (CI 95.0–98.4%)         49.9% (CI 45.1–54.7%)		Folliculitis	1780	1005	38.0	73.7	99.9% (CI 99.8-100.1%)	99.2% (CI 98.8–99.6%)	39.8% (CI 37.6-42.1%)	71.3% (CI 69.2-73.4%)
. 421 387 53.3 46.8 97.6% (CI 96.2–99.1%) 96.7% (CI 95.0–98.4%) 49.9% (CI 45.1–54.7%)		Herpes simplex	1450	887	34.0	45.5	97.2% (CI 96.3-98.0%)	89.9% (CI 88.3–91.4%)	13.7% (CI 12.0-15.5%)	32.2% (CI 29.8-34.6%)
		Herpes zoster	421	387	53.3	46.8	97.6% (CI 96.2-99.1%)	96.7% (CI 95.0-98.4%)	49.9% (CI 45.1-54.7%)	65.6% (CI 61.0-70.1%)

of the Algorithm
3 Accuracies o
p-1 and Top-
ataset and To
s of the NIA Da
Demographics
(continued)
Table 1

Category	Disease	NIA Dataset				Algo. (Binary)		Algo. (Multiclass)	
		No. of Images	No. of Cases	Average Age	Male (%)	TOP-1	TOP-3	TOP-1	TOP-3
	Impetigo	1755	745	0.9	58.4	99.4% (CI 99.1-99.8%)	96.1% (CI 95.2-97.0%)	28.0% (CI 25.9-30.1%)	42.6% (CI 40.3-44.9%)
	Ingrown nail	292	989	15.1	60.2	100.0% (CI 100.0-100.0%)	99.7% (CI 99.4-100.1%)	52.5% (CI 49.0-56.1%)	74.6% (CI 71.6-77.7%)
	Molluscum contagiosum	2943	1653	7.1	52.8	100.0% (CI 99.9-100.0%)	99.7% (CI 99.5–99.9%)	55.8% (CI 54.0-57.6%)	78.6% (CI 77.1-80.0%)
	onychomycosis	2865	1212	43.9	53.5	100.0% (CI100.0-100.0%)	99.9% (CI 99.8–100.0%)	73.8% (CI 72.1-75.4%)	94.8% (CI 93.9-95.6%)
	Pityriasis rosea	1355	675	28.9	49.6	99.8% (CI 99.5-100.0%)	99.3% (CI 98.9–99.8%)	31.7% (CI 29.2-34.1%)	58.2% (CI 55.5-60.8%)
	Tinea corporis	483	317	45.7	55.2	98.8% (CI 97.8-99.7%)	97.1% (CI 95.6-98.6%)	42.4% (CI 38.0-46.9%)	62.5% (CI 58.2-66.8%)
	Tinea pedis	248	155	48.3	64.5	98.0% (CI 96.2-99.7%)	94.4% (CI 91.5–97.2%)	29.0% (CI 23.4-34.7%)	48.4% (CI 42.2-54.6%)
	Tinea versicolor	2009	1043	21.9	73.2	100.0% (CI 100.0-100.0%)	99.8% (CI 99.6-100.0%)	7.8% (CI 6.6–8.9%)	20.8% (CI 19.0-22.6%)
	Varicella	1042	375	11.3	65.1	100.0% (CI100.0-100.0%)	100.0% (CI 100.0-100.0%)	25.5% (CI 22.9-28.2%)	43.8% (CI 40.7-46.8%)
	Verruca plana	170	73	33.2	42.5	100.0% (CI 100.0-100.0%)	98.8% (CI 97.2-100.4%)	0.0% (CI 0.0-0.0%)	8.8% (CI 4.6-13.1%)
	Total (Infectious Disorders)	14,833	27,374	24.2	56.8	*99.3% b99.6%	<sup>a</sup> 97.7% <sup>b</sup> 98.2%	a38.5% b48.4%	<sup>a</sup> 58.1% <sup>b</sup> 69.8%
Allergic Disorders	Atopic dermatitis	20,449	10,440	14.1	64.9	99.9% (CI 99.9-100.0%)	99.6% (CI 99.5-99.7%)	47.5% (CI 46.8-48.2%)	67.7% (CI 67.1-68.4%)
	Contact dermatitis	2206	1022	46.8	36.3	100.0% (CI100.0-100.0%)	98.9% (CI 98.4-99.3%)	16.1% (CI 14.6–17.7%)	47.9% (CI 45.8-50.0%)
	Insect bite	1319	730	9.6	52.5	100.0% (CI 100.0-100.0%)	99.4% (CI 99.0–99.8%)	15.4% (CI 13.4-17.3%)	38.7% (CI 36.0-41.3%)
	Lichen simplex chronicus	151	59	51.4	47.5	99.3% (CI 98.0-100.6%)	97.4% (CI 94.8–99.9%)	3.3% (CI 0.5-6.2%)	29.8% (CI 22.5-37.1%)
	Nummular eczema	3725	1844	25.7	53.6	99.3% (CI 99.0-99.5%)	96.2% (CI 95.6-96.8%)	21.7% (CI 20.4-23.0%)	40.2% (CI 38.7-41.8%)
	Pompholyx	983	363	17.4	46.3	99.9% (CI 99.7-100.1%)	99.4% (CI 98.9–99.9%)	17.2% (CI 14.8–19.6%)	49.0% (CI 45.9-52.2%)
	Prurigo nodularis	2684	924	18.3	62.7	99.8% (CI 99.7-100.0%)	99.1% (CI 98.7-99.4%)	36.7% (CI 34.8-38.5%)	57.5% (CI 55.7-59.4%)
	Seborrheic dermatitis	1566	843	45.2	53.9	99.7% (CI 99.5-100.0%)	98.4% (CI 97.8-99.0%)	10.5% (CI 9.0-12.0%)	29.3% (CI 27.1-31.6%)
	Urticaria	3020	1340	23.3	58.2	100.0% (CI 100.0-100.0%)	99.7% (CI 99.5-99.9%)	47.0% (CI 45.2-48.8%)	68.4% (CI 66.8-70.1%)
	Urticaria pigmentosa	1718	1030	1.7	63.0	99.9% (CI 99.7-100.0%)	99.4% (CI 99.1–99.8%)	40.2% (CI 37.9-42.5%)	58.5% (CI 56.2-60.8%)
	Total (Allergic Disorders)	18,595	37,821	18.6	60.1	8.99.8% b99.8%	<sup>8</sup> 98.7% <sup>b</sup> 99.1%	°25.6% b38.4%	a48.7% b59.5%
Miscellaneous	Alopecia areata	4237	3014	22.7	53.7	100.0% (CI100.0-100.0%)	99.8% (CI 99.7-100.0%)	69.3% (CI 67.9-70.7%)	91.9% (CI 91.1-92.7%)
	Androgenic alopecia	2150	1928	40.9	99.8	100.0% (CI100.0-100.0%)	99.9% (CI 99.8–100.0%)	87.5% (CI 86.1-88.9%)	98.4% (CI 97.9–98.9%)
	Guttate psoriasis	354	184	32.3	38.6	100.0% (CI 100.0-100.0%)	100.0% (CI 100.0-100.0%)	44.1% (CI 38.9-49.2%)	71.5% (CI 66.8-76.2%)
	Idiopathic guttate hypomelanosis	1639	762	62.1	26.9	100.0% (CI 100.0-100.0%)	99.2% (CI 98.8-99.6%)	39.3% (CI 36.9-41.7%)	65.8% (CI 63.5-68.1%)
	Lichen striatus	1732	1211	7.1	36.3	99.9% (CI 99.7-100.0%)	99.9% (CI 99.7–100.0%)	62.3% (CI 60.0-64.6%)	80.6% (CI 78.7-82.5%)
	Nail dystrophy	3239	1549	18.9	52.2	100.0% (CI100.0-100.0%)	99.7% (CI 99.5-99.9%)	58.6% (CI 56.9-60.3%)	95.5% (CI 94.7-96.2%)
	Onycholysis	182	84	45.8	39.3	100.0% (CI100.0-100.0%)	100.0% (CI 100.0-100.0%)	72.5% (CI 66.0-79.0%)	94.5% (CI 91.2-97.8%)
	Palmoplantar pustulosis	159	109	46.9	33.9	100.0% (CI100.0-100.0%)	100.0% (CI 100.0-100.0%)	77.4% (CI 70.9-83.9%)	96.9% (CI 94.1-99.6%)
	Parapsoriasis	154	116	45.2	45.7	99.4% (CI 98.1-100.6%)	98.7% (CI 96.9-100.5%)	40.3% (CI 32.5-48.0%)	67.5% (CI 60.1-74.9%)
	Pityriasis lichenoides chronica	2051	818	12.0	64.4	100.0% (CI 100.0-100.0%)	99.8% (CI 99.6-100.0%)	7.0% (CI 5.9-8.1%)	36.4% (CI 34.3-38.5%)
	Pityriasis lichenoides et varioliformis acuta	482	213	11.3	71.8	100.0% (CI 100.0–100.0%)	100.0% (CI100.0–100.0%)	10.2% (CI 7.5–12.9%)	36.1% (CI 31.8-40.4%)
	Psoriasis	11,073	5258	33.2	65.0	99.6% (CI 99.4–99.7%)	97.6% (CI 97.3–97.9%)	44.6% (CI 43.7-45.6%)	65.4% (CI 64.5-66.3%)
	Rosacea	2450	1321	50.9	22.5	99.9% (CI 99.7–100.0%)	99.3% (CI 99.0%-99.7%)	44.9% (CI 42.9%-46.9%)	77.2% (CI 75.5%-78.8%)
	Scar	2887	2183	21.6	35.1	99.0% (CI 98.6-99.4%)	96.2% (CI 95.5-96.9%)	32.1% (CI 30.4-33.8%)	56.7% (CI 54.9-58.5%)

able 1 (continued) | Demographics of the NIA Dataset and Top-1 and Top-3 Accuracies of the Algorithm

Category	Disease	NIA Dataset				Aigo. (binary)		Aigo. (Multiclass)	
		No. of Images No. of C	No. of Cases	Average Age Male (%) TOP-1	Male (%)	TOP-1	TOP-3	TOP-1	TOP-3
	Vitiligo	4980	2725	25.7	54.1	99.9% (CI 99.9-100.0%)	99.9% (CI 99.9–100.0%) 99.3% (CI 99.1–99.5%) 62.3% (CI 61.0–63.7%) 83.6% (CI 82.6–84.6%)	62.3% (CI 61.0-63.7%)	83.6% (CI 82.6-84.6%)
	Total (Miscellaneous)	21,475	37,769	29.0	55.1	%8.66 <sup>d</sup> %8.66 <sup>e</sup>	%8.86 <sup>d</sup> %6.99 <sup>e</sup>	°50.2% °50.8%	a74.5% b74.4%
Total		152,443	92,004	27.2	52.2	*96.6% b98.2%	<sup>a</sup> 95.1% <sup>b</sup> 96.2%	a43.3% b47.9%	%9.07 <sup>d</sup> %8.89°
A 95% confidence i	Somitidence interval (C)) was reported using the binomial distribution method. Bhary class accuracy refers to the correctness of predictions in determining whether a case is cancerous or not, while multi-class accuracy measures the correctness of predictions in	oution method. Binary	r class accuracy r	efers to the correctr	ness of predictic	ons in determining whether a cas	se is cancerous or not, while mult	i-class accuracy measures the	e correctness of predictions in

dentifying the specific disease name accurately. Only four major skin cancer types were included under the category of malignancy, and other rare or less common skin cancers were not covered in the NIA dataset.

Wart is included in both benign tumors and infectious diseases

77.0-79.4%), predicted by three differentials, was presented as the ideal maximum value achievable in real-world settings. If users capture only lowquality images, the sensitivity could be lower<sup>15,23</sup>. Conversely, in practice, repeated testing of a lesion over days may increase sensitivity.

Next, regarding specificity, the minimum specificity was estimated under the assumption that there are no true negatives (= all false positives) in the usage data. The analysis of usage records in Korea showed that the algorithm predicted malignancy at a rate of 12.0% (95% CI, 11.8-12.1%) based on three differentials. Given the relatively low prevalence of cancer, if we assume all malignancy predictions by the algorithm are false positives, the specificity was estimated at 88.0% (95% CI, 87.9–88.2%). (Supplementary Table 4) This figure (88.0%) is lower than the specificity reported for the NIA dataset (93.0%; Table 1). At first glance, benign tumors requiring hospital visits may seem harder for AI to diagnose than various skin conditions seen in daily life. However, real-world use includes out-ofdistribution scenarios, likely affecting the degradation of AI performance. On the other hand, actual specificity may be slightly higher than our 88.0% estimate, as users often confirm malignant results through repeated tests before hospital visits.

From the perspective of disease screening, WHO tuberculosis guidelines set minimal requirements of 90% sensitivity and 70% specificity<sup>24</sup>. Similarly, the Breast Cancer Surveillance Consortium benchmarks highlight 86.9% sensitivity and 88.9% specificity for breast cancer screening<sup>25</sup>. However, for skin cancer screening, no precise guidelines for the sensitivity and specificity currently exist<sup>26</sup>. Furthermore, concerns about overdiagnosis in dermatologist-led skin cancer screenings highlight the need to discuss using algorithms with lower real-world performance. As seen in Fig. 2a, the higher malignancy rate on the map may be related to greater algorithm usage for skin cancer, similar to how an increase in dermatology clinics is associated with a higher regional incidence of melanoma<sup>27,28</sup>. However, unlike human physicians, algorithms can be adjusted to operate with either very high specificity or low by modifying the threshold. For example, in scenarios where concerns about overdiagnosis, the threshold could be raised to identify only cancers with the highest diagnostic certainty, particularly in populations with limited access to healthcare. From this perspective, there should be an effort to find proper settings by each region and demonstrate the improvement of clinical outcomes (mortality, morbidity, and costs).

The usage statistics revealed significant regional differences in the types of diseases predicted by the algorithm. (Figs. 2, 3, Supplementary Table 3) Neoplastic disorders were more commonly predicted in Asia, Europe, and North America. (Fig. 2) Premalignant conditions such as actinic keratosis were observed at higher rates in Australia and North America. (Fig. 3) Interestingly, in line with these findings, users from the EU, North America, and Oceania showed higher sensitivity in the global reader test compared to those from other regions. (Fig. 1b) In contrast, infectious diseases were more frequently observed in regions such as Northern Africa and the Middle East. (Fig. 2c) These regional differences reflect variations in disease prevalence, the age demographics of users, and the diseases users are particularly concerned about in each region. For example, in South Korea, despite the low prevalence of skin cancer, high interest in skin cancer in the media may lead to a higher malignancy ratio as shown in Fig. 2a. These data, collected before patients even visit the clinic, can offer more accurate insights into the prevalence and interest in specific skin conditions. The global burden of disease study has been attempted, but only for certain disease groups, with no individual approach to dermatological diseases<sup>29-31</sup>. This indicates that AIbased big data analytics could significantly contribute to understanding skin disease trends globally.

Our study has several limitations. The first part of the study was limited to patients with skin types III and IV, which account for the vast majority of skin types in Korea. Therefore, we were unable to provide stratified data by race and skin type, especially in the population of dark skin tones<sup>32</sup>. Additional studies are required to evaluate the sensitivity for skin cancer in white and black populations.




Fig. 1 | ROC curve for determining malignancy using the NIA dataset and SNU test dataset. The performance of the algorithm, calculated based on Top-1 or Top-3 predictions, is drawn separately in the figure. a TEST = Benign and malignant tumors in the NIA dataset (51,038 images, 33 diseases). b TEST = SNU Test Dataset (240 images, 80 diseases); The results from six continents are based on 61,066 assessments

collected from 138 countries. Country-level results are presented only for the top 10 countries with the highest number of responses. Detailed data by country can be found in Supplementary Table 3. AF Africa, AS Asia, BR Brazil, DE Germany, ES Spain, EU Europe, FR France, HU Hungary, IT Italy, KR South Korea, NA North America, OC Oceania, PL Poland, RU Russia, SA South America, US United States.

Second, the NIA dataset does not include less common skin cancers beyond the four major types (e.g. Merkel cell carcinoma, Kaposi sarcoma). According to 20 years of incidence statistics in Korea, these other types account for approximately 11.3% of all skin cancers<sup>33</sup>. In particular, early detection with AI can be beneficial for rare but very poor-prognosis skin cancers such as cutaneous angiosarcoma<sup>34</sup>. Therefore, rare cancers not represented in the NIA dataset should be collected and analyzed using appropriate statistical sample size considerations to ensure sufficient power and validity.

Third, the sensitivity and specificity calculated in this study needs to be re-evaluated through further digital transformation efforts, separately for each indication. The global study lacked a gold standard in order to calculate sensitivity and specificity. Ideally, users could provide feedback on final diagnosis based on clinical follow-up, laboratory work-up or final histopathological assessment. Further validation should be tried individually in each country, tailored to the healthcare environment<sup>35</sup>.

Fourth, in terms of multi-class results, the algorithm achieved Top-1 and Top-3 accuracies of 43.3% and 66.6% on the NIA dataset. Although the multi-class performance of the algorithm was validated using the large dataset, its real-world accuracy also needs to be reassessed in further studies.

Fifth, because of this being the study to evaluate real-use of global users of a single algorithm, it was challenging to determine the best approach. Since usage varies over time, it is displayed as the disease ratio within each country.

Sixth, although this was a global study, data from Africa, South America, and Oceania were relatively underrepresented, which may reflect regional differences in population size, access to digital healthcare, and overall engagement with digital health initiatives.

Finally, while the algorithm was designed to prioritize high specificity, it may be perceived as insufficient from the perspective of maximizing sensitivity. Although high sensitivity has been favored to avoid missing malignant cases, this approach often results in a high false-positive rate, as seen in the case of MelaFind<sup>17</sup>. In the context of AI tools that may be used frequently by laypersons without clinical oversight, insufficient specificity could amplify overdiagnosis<sup>27</sup> and unnecessary anxiety. Therefore, our specificity-focused design aligns with concerns about overdiagnosis and

false alarms, particularly in low-risk populations. However, it limits the algorithm's ability to capture all true positives.

In conclusion, using a national-scale curated dataset and real-world usage data, the performance of AI in diagnosing skin cancer in Korea could be estimated at 78.2% (95% CI, 77.0–79.4%) sensitivity and 88.0% (95% CI, 87.9–88.2%) specificity. In multi-class classification, our algorithm achieved Top-1 and Top-3 accuracies of 43.3% and 66.6%, respectively, replicating the results obtained from the past small study<sup>4</sup>. Furthermore, this study highlights the potential of AI algorithms to provide a global perspective on skin diseases, offering a quantitative reflection of regional variations using AI-based big data analytics. Further research is needed to identify clinical settings where AI can effectively improve clinical outcomes. Additionally, the need for randomized controlled trials (RCTs) and validation in underrepresented regions, such as Africa and South America, must be explicitly emphasized to ensure the algorithm's effectiveness and generalizability across diverse populations.

## Methods

b

This study adheres to the STARD 2015 guidelines and was approved by the Kangnam Sacred Hospital Institutional Review Board (2021-10-011, 2024-02-028-004) as a retrospective study.

# **Datasets for validation**

1. The NIA dataset consists of 152,443 clinical photographs (2001–2021) taken with professional DSLR cameras by dermatology residents or professional photographers from 92,004 random cases, covering 70 distinct skin diseases<sup>36</sup>. (Table 1) Among these, 4250 cases (4.6%) are malignancies, including 734 melanomas, 1804 basal cell carcinomas (BCC), 1601 invasive squamous cell carcinomas (SCC), and 111 in situ squamous cell carcinomas (Bowen's disease) cases. The number of malignancies in the NIA dataset is comparable to Korea's annual average number of skin cancer cases (4498) based on 20 years of statistics<sup>33</sup>. Assuming 80% sensitivity and a sample size of 4250, the 95% confidence interval for precision was ±1.18% (Wilson score method). Diagnoses were validated based on clinical diagnoses or

S
<u>е</u> .
≠
⋤
ಠ
Ŭ
0
Ē
a
ᄫ
₫
.⊑
₹
0
O
⊳
7
5
∓
<u>.</u> 2
ğ
<u> </u>
۵
Ţ
<u>α</u>
્.ŏ
-
ູເ
Ε
ᄛ
ξ
ō
<u> </u>
⋖
Φ
윤
· _
2
۳
౼
ĕ
_⊆
ā
₫
0
Ś
윽
0
ğ
ن
ĕ
ä
ě
.9
Ω
of of
S
ğ
.으
ヹ
2
ŏ
۲
=
N
<u>o</u>
₫
Ta
_

	Total Queries	Benigns	Allergies	Infections	Malignancies	Familiared I I
Korea, Republic of	382,602	249,395 (65.2%, CI 65.0-65.3%)	27,069 (7.1%, CI 7.0–7.2%)	27,570 (7.2%, CI 7.1–7.3%)	7957 (2.1%, CI 2.0-2.1%)	3.1% (CI 3.0-3.2%)
raly .	151,574	79,350 (52.4%, CI 52.1–52.6%)	16,232 (10.7%, CI 10.6–10.9%)	15,258 (10.1%, CI 9.9–10.2%)	3550 (2.3%, CI 2.3-2.4%)	4.3% (CI 4.1-4.4%)
United States	105,233	40,957 (38.9%, CI 38.6–39.2%)	14,888 (14.1%, CI 13.9–14.4%)	13,252 (12.6%, CI 12.4–12.8%)	2953 (2.8%, CI 2.7-2.9%)	6.7% (CI 6.5-7.0%)
Germany	100,285	51,000 (50.9%, CI 50.5–51.2%)	12,027 (12.0%, CI 11.8–12.2%)	10,413 (10.4%, CI 10.2–10.6%)	1935 (1.9%, CI 1.8–2.0%)	3.7% (CI 3.5–3.8%)
France (	68,408	30,430 (44.5%, CI 44.1–44.9%)	10,399 (15.2%, CI 14.9–15.5%)	8,538 (12.5%, CI 12.2-12.7%)	1,393 (2.0%, CI 1.9–2.1%)	4.4% (CI 4.2–4.6%)
Russian Federation	64,997	17,925 (27.6%, CI 27.2–27.9%)	13,723 (21.1%, CI 20.8–21.4%)	10,653 (16.4%, CI 16.1–16.7%)	619 (1.0%, CI 0.9-1.0%)	3.3% (CI 3.1-3.6%)
Spain	56,347	27,667 (49.1%, CI 48.7–49.5%)	6210 (11.0%, CI 10.8-11.3%)	5383 (9.6%, CI 9.3–9.8%)	1142 (2.0%, CI 1.9–2.1%)	4.0% (CI 3.7-4.2%)
Brazil	54,974	18,305 (33.3%, CI 32.9–33.7%)	8063 (14.7%, CI 14.4–15.0%)	7642 (13.9%, CI 13.6–14.2%)	841 (1.5%, CI 1.4–1.6%)	4.4% (CI 4.1–4.7%)
United Kingdom	54,028	23,692 (43.9%, CI 43.4–44.3%)	6939 (12.8%, CI 12.6–13.1%)	6127 (11.3%, CI 11.1–11.6%)	1479 (2.7%, CI 2.6–2.9%)	5.9% (CI 5.6-6.2%)
Hungary 4	47,937	21,224 (44.3%, CI 43.8–44.7%)	7418 (15.5%, CI 15.2–15.8%)	6168 (12.9%, CI 12.6–13.2%)	759 (1.6%, CI 1.5–1.7%)	3.5% (CI 3.2-3.7%)
Europe 8	810,181	376,874 (46.5%, CI 46.4–46.6%)	108,783 (13.4%, CI 13.4–13.5%)	93,324 (11.5%, CI 11.4–11.6%)	15,073 (1.9%, CI 1.8–1.9%)	3.8% (CI 3.8-3.9%)
Asia	533,106	295,687 (55.5%, CI 55.3–55.6%)	54,081 (10.1%, CI 10.1–10.2%)	53,415 (10.0%, CI 9.9-10.1%)	9,714 (1.8%, CI 1.8–1.9%)	3.2% (CI 3.1–3.2%)
North America	170,948	65,039 (38.0%, CI 37.8–38.3%)	24,904 (14.6%, CI 14.4–14.7%)	21,972 (12.9%, CI 12.7–13.0%)	4466 (2.6%, CI 2.5–2.7%)	6.4% (CI 6.2–6.6%)
South America	96,373	31,100 (32.3%, CI 32.0-32.6%)	15,339 (15.9%, CI 15.7–16.1%)	14,274 (14.8%, CI 14.6–15.0%)	1,344 (1.4%, CI 1.3-1.5%)	4.1% (CI 3.9-4.4%)
Africa	48,483	10,858 (22.4%, CI 22.0–22.8%)	7485 (15.4%, CI 15.1–15.8%)	8284 (17.1%, CI 16.8–17.4%)	460 (0.9%, CI 0.9–1.0%)	4.1% (CI 3.7-4.4%)
Oceania (	31,941	14,943 (46.8%, CI 46.2–47.3%)	3611 (11.3%, CI 11.0–11.7%)	2739 (8.6%, CI 8.3–8.9%)	549 (1.7%, CI 1.6-1.9%)	3.5% (CI 3.3-3.8%)
Total	1,691,032	794,501 (47.0%, CI 46.9–47.1%)	214,203 (12.7%, CI 12.6–12.7%)	194,008 (11.5%, CI 11.4–11.5%)	31,606 (1.9%, CI 1.8–1.9%)	3.8% (CI 3.8-3.9%)
95% confidence interval (CI) was reported using the binomial distribution method. This table shows statistics for the 10 countries with the highest usage and 6 continents. The proportions of benign tumors, malignant tumors, allergic disorders, and infectious an						
a hopings accompanie of the	as reported using the bi	nomial distribution method. This table shows ${\mathfrak t}$	statistics for the 10 countries with the highest us	A 95% confidence interval (C)) was reported using the binomial distribution method. This table shows statistics for the 10 countries with the highest usage and 6 continents. The proportions of benign tumors, malignant tumors, allergic disorders, and infectious disorders	tumors, malignant tumors, allergic disorc	ders, and infectio




Fig. 2 | Global distribution of disease predictions - four disease groups. A worldwide map illustrating the differences in the algorithm's predictions across various disease groups. This reflects both the interest in the disease and its

prevalence. Interactive demo is available at https://whria78.github.io/nia/demo a Malignant tumors (countries with fewer than 1000 requests were excluded) b Benign tumors c Infectious diseases d Allergic diseases.

pathology reports in cases of malignancy. The NIA dataset was compiled from 9 university hospitals in Korea. From each clinical image, the lesion of interest was manually cropped to generate standardized square images. These cropped images were then reviewed by two dermatologists, and only those deemed consistent with the diagnosis were included. Images that were blurry, poorly focused, diagnostically ambiguous, or not included in the predefined set of 70 diagnoses were excluded. A total of 52 board-certified dermatologists and 35 dermatology residents participated in data processing.

2. The SNU test dataset consists of 240 clinical photographs, covering 80 distinct diseases. (Supplementary Table 1) The dataset includes 40 malignancy cases, comprising 7 Bowen's disease, 3 keratoacanthoma, 8 BCC, 8 SCC, and 14 melanoma cases. Both malignant and benign tumors had histopathological confirmation, while other benign non-tumoral conditions were diagnosed clinically. This public dataset was compiled in a previous study that includes the reader test results from 21 dermatologists and 23 laypersons<sup>4</sup>. In this study, a global reader test was conducted using the same SNU test dataset in a mobile environment (https://www.modelderm.com/# quiz; Supplementary Note 1). The global reader test consists of image-based questions, randomly sorted and presented in a binary (yes/no) format, asking whether the condition is cancerous. To prevent cheating (e.g., using multiple devices to find the correct answers), each installation of the app presents a unique, shuffled order of questions.

# Global usages study

We analyzed 1,691,032 requests submitted over 2.5 years (2022.7.7–2025.1.18) by 371,757 global users to the mobile app (https://modelderm.com). (Table 2, Supplementary Table 3) At no point were potentially identifiable data such as user registration information, device identifiers, or patient images collected or stored, and all data used for analysis remained at the level of de-identified server logs. As the submission was fully anonymized, informed consent was not required under current regulatory standards (U.S. Common Rule, 45 CFR §46.104[d][4]; European GDPR, Recital 26). All user-submitted images were included in the analysis, including those that received a low-quality warning from the app, which may have introduced variability in

image quality and potentially affected diagnostic performance. Algorithm's predictions were categorized into five groups: benign tumors, malignant tumors, infectious diseases, allergic diseases, and miscellaneous. (Table 1) Wart was counted under both benign tumors and infectious diseases because it should be distinguished from verrucous skin cancer.

## **Algorithm**

The NIA and SNU test dataset were tested using ModelDerm Build2024 (https://modelderm.com, Supplementary Note 1). For global usage statistics, Build2024 was used during 2024–2025, while Build2021<sup>15</sup> was used during 2022–2023. The architecture of the algorithm is an ensemble of ResNet variants. The algorithm was developed using an R-CNN-based approach, designed to incorporate out-of-distribution data as much as possible. This method involved manually annotating lesions from numerous R-CNN predictions, extracting them from a vast collection of internet and public images.

## Statistical analysis

Model performance was evaluated using sensitivity, specificity, and top-n accuracy. Sensitivity and specificity for determining malignancy can be derived from one prediction (Top-1) or three predictions (Top-3) of the algorithm. The results of sensitivity and specificity were calculated using the Top-3. The ROC curve was drawn using the malignancy score which is composed of the output for malignant and premalignant diseases4. A 95% confidence interval (CI) was reported for all results using the binomial distribution method. When reporting the average, the macro-averaged mean is used unless otherwise indicated, and the micro-averaged mean is explicitly specified when applicable. The standard error for a proportion is the square root of the proportion times its complement, divided by the sample size, and the z-score of 1.96 is used to calculate the 95% confidence interval. To account for Type I error when performing Chi-square tests to sequentially compare values across six continents, we applied the Bonferroni correction by multiplying the *p*-value by 5. All statistical analyses were performed using R (version 4.3.3; https://www.r-project. org/). ROC curves were created using matplotlib (version 3.10.0; https://matplotlib.org/).




Fig. 3 | Global distribution of 10 common conditions predicted by the algorithm. A worldwide map illustrating how the algorithm's predictions and usages vary across common diseases. The selection of the 10 common diseases was based on algorithm

usage as shown in Supplementary Table 6: a melanocytic nevus,  $\mathbf{b}$  seborrheic keratosis,  $\mathbf{c}$  cherry hemangioma,  $\mathbf{d}$  dermatofibroma,  $\mathbf{e}$  folliculitis,  $\mathbf{f}$  wart,  $\mathbf{g}$  lentigo,  $\mathbf{h}$  hemangioma,  $\mathbf{i}$  urticaria, and  $\mathbf{j}$  actinic keratosis.

# **Data availability**

ModelDerm Build2024 can be freely tested on mobile devices or PCs at: https://modelderm.com. Interactive demo showing the global distribution of skin disease predictions: https://whria78.github.io/nia/demo. The SQL

dump of usage logs is available at: <a href="https://github.com/whria78/nia">https://github.com/whria78/nia</a>. The clinical images in the NIA dataset are a private collection from nine universities and cannot be publicly shared. The dataset was created with the support of the National Information Society Agency (NIA).

Received: 12 February 2025; Accepted: 27 August 2025; Published online: 08 October 2025

#### References

- Salinas, M. P. et al. A systematic review and meta-analysis of artificial intelligence versus clinicians for skin cancer diagnosis. NPJ Digital Med. 7, 125 (2024).
- Esteva, A. et al. Dermatologist-level classification of skin cancer with deep neural networks. *Nature* 542, 115–118 (2017).
- Haenssle, H. A. et al. Man against machine reloaded: performance of a market-approved convolutional neural network in classifying a broad spectrum of skin lesions in comparison with 96 dermatologists working under less artificial conditions. *Ann. Oncol.* 31, 137–143 (2020).
- Han, S. S. et al. Augmented intelligence dermatology: deep neural networks empower medical professionals in diagnosing skin cancer and predicting treatment options for 134 skin disorders. *J. Investig. Dermatol.* 140, 1753–1761 (2020).
- Liu, Y. et al. A deep learning system for differential diagnosis of skin diseases. *Nat. Med.* 26, 900–908 (2020).
- Giotis, I. et al. MED-NODE: a computer-assisted melanoma diagnosis system using non-dermoscopic images. Expert Syst. Appl. 42, 6578–6585 (2015).
- Kawahara, J., Daneshvar, S., Argenziano, G. & Hamarneh, G. Sevenpoint checklist and skin lesion classification using multitask multimodal neural nets. *IEEE J. Biomed. Health Inform.* 23, 538–546 (2018).
- Tschandl, P., Rosendahl, C. & Kittler, H. The HAM10000 dataset, a large collection of multi-source dermatoscopic images of common pigmented skin lesions. Sci. Data 5, 1–9 (2018).
- Daneshjou, R., Yuksekgonul, M., Cai, Z. R., Novoa, R. & Zou, J. Y. Skincon: a skin disease dataset densely annotated by domain experts for fine-grained debugging and analysis. Adv. Neural Inf. Process. Syst. 35, 18157–18167 (2022).
- Ricci Lara, M. A. et al. A dataset of skin lesion images collected in Argentina for the evaluation of Al tools in this population. Sci. Data 10, 712 (2023).
- Chiou, A. S. et al. Multimodal Image Dataset for Al-based Skin Cancer (MIDAS) Benchmarking. NEJM Al. 2, Aldbp2400732 (2024).
- Gottfrois, P. et al. in International Conference on Medi cal Image Computing and Computer-Assisted Intervention. 703–712 (Springer, 2015).
- 13. Codella, N. C. et al. In 2018 IEEE 15th international symposium on biomedical imaging (ISBI 2018). 168–172 (IEEE, 2018).
- Brinker, T. J. et al. Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. *Eur. J. Cancer* 111, 30–37 (2019).
- Han, S. S. et al. The degradation of performance of a state-of-the-art skin image classifier when applied to patient-driven internet search. Sci. Rep. 12, 16260 (2022).
- Han, S. S. et al. Assessment of deep neural networks for the diagnosis of benign and malignant skin neoplasms in comparison with dermatologists: a retrospective validation study. *PLoS Med.* 17, e1003381 (2020).
- Venkatesh, K. P., Kadakia, K. T. & Gilbert, S. Learnings from the first Al-enabled skin cancer device for primary care authorized by FDA. npj Digital Med. 7, 156 (2024).
- Hidalgo, L. et al. Creating a dermatologic database for artificial intelligence, a Chilean experience, and advice from ChatGPT. *JEADV Clin Pract.* 4, 296–298 (2025).
- 19. Navarrete-Dechent, C. et al. Automated dermatological diagnosis: hype or reality?. *J. investi. Dermatol.* **138**, 2277 (2018).
- Topol, E. J. Welcoming new guidelines for Al clinical research. *Nat. Med.* 26, 1318–1320 (2020).
- Han, S. S. et al. Evaluation of artificial intelligence–assisted diagnosis of skin neoplasms: a single-center, paralleled, unmasked, randomized controlled trial. *J. Investig. Dermatol.* 142, 2353–2362. e2352 (2022).

- 22. Han, R. et al. Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping review. *Lancet Digital Health* **6.** e367–e373 (2024).
- 23. Muñoz-López, C. et al. Performance of a deep neural network in teledermatology: a single-centre prospective diagnostic study. *J. Eur. Acad. Dermatol. Venereol.* **35**, 546–553 (2021).
- Organization, W. H. High priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting, 28-29 April 2014, Geneva, Switzerland. (World Health Organization, 2014).
- Lehman, C. D. et al. National performance benchmarks for modern screening digital mammography: update from the Breast Cancer Surveillance Consortium. *Radiology* 283, 49–58 (2017).
- Sangers, T. E. et al. Position statement of the EADV Artificial Intelligence (Al) Task Force on Al-assisted smartphone apps and web-based services for skin disease. J. Eur. Acad. Dermatol. Venereol. 38, 22–30 (2024).
- 27. Welch, H. G., Mazer, B. L. & Adamson, A. S. The rapid rise in cutaneous melanoma diagnoses. *N. Engl. J. Med.* **384**, 72–79 (2021).
- Navarrete-Dechent, C. & Lallas, A. Overdiagnosis of melanoma: is it a real problem? *Dermatol. Pract. Conceptual* 13, e2023246 (2023).
- 29. Flohr, C. & Hay, R. Putting the burden of skin diseases on the global map. *Br J Dermatol.* **184**, 189–190 (2021).
- Murray, C. J. The global burden of disease study at 30 years. *Nat. Med.* 28, 2019–2026 (2022).
- Wyper, G. The global burden of disease study and Population Health Metrics. Popul. Health Metr. 22, 1–5 (2024).
- 32. Daneshjou, R. et al. Disparities in dermatology Al performance on a diverse, curated clinical image set. Sci. Adv. 8, eabq6147 (2022).
- Kwon, S. H. et al. Incidence and survival rates of primary cutaneous malignancies in Korea, 1999–2019: a nationwide population-based study. *J. Dermatol.* 51, 532–538 (2024).
- 34. Cao, J., Wang, J., He, C. & Fang, M. Angiosarcoma: a review of diagnosis and current treatment. *Am. J. cancer Res.* **9**, 2303 (2019).
- Smak Gregoor, A. M. et al. An artificial intelligence based app for skin cancer detection evaluated in a population based setting. NPJ digital Med. 6, 90 (2023).
- Kim, D.-W., Jang, G. & Kim, H.-J. Development of CNN-based Semantic Segmentation Algorithm for Crop Classification of Korean Major Upland Crops Using NIA AI HUB (IEEE, 2025).

#### **Acknowledgements**

S.S. Han and S.I. Cho have full access to all the data used in the study and take responsibility for the integrity of the data and accuracy of the data analysis.

# **Author contributions**

S.S. Han, J.I. Na, and S.I. Cho designed the experiments.S.I. Cho, J. Na, S.H. Kim, and S.S. Han prepared the datasets and performed the experiments.S.S. Han, S.I. Cho, N. Cristian, J. Na, F. Gröger, A.A. Navarini, M.S. Kim, D.H. Lee, J.H. Lee, J. Kim, C.H. Won, K.N. Bae, J.B. Lee, H.S. Yoon, S.E. Chang, and S.H. Kim interpreted the results.S.S. Han, S.I. Cho, N. Cristian, J. Na, F. Gröger, A.A. Navarini, M.S. Kim, D.H. Lee, J.H. Lee, J. Kim, C.H. Won, K.N. Bae, J.B. Lee, H.S. Yoon, S.E. Chang, and S.H. Kim wrote the manuscript and prepared the figures.S.S. Han, J. Na, S.I. Cho, and N. Cristian supervised the entire experiment.All authors approved the final version of the manuscript.

#### Competing interests

S.S. Han is the founder and CEO of IDerma, Inc.; S.I. CHo is an employee of Lunit. A.A.N. is a shareholder of Derma2Go AG and Derma.One GmbH. All other authors have no conflict of interest.

## **Additional information**

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41746-025-01980-w.

**Correspondence** and requests for materials should be addressed to Seong Hwan Kim or Jung Im Na.

Reprints and permissions information is available at

http://www.nature.com/reprints

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

© The Author(s) 2025